Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 66 of 114

  1. Moxifloxacin

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease (COPD).

    phase 3 small molecule active

    1 trial

  2. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  3. Mycophenolate Mofetil

    Cardiff Oncology

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  4. MyelomaXIV

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. Myocet

    Teva Pharma GmbH

    Early Primary Breast Cancer

    phase 3 small molecule completed

    1 trial

  6. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  7. N-Acetylcysteine

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  8. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials

  9. N-Acetylcysteine (NAC) Treatment

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  10. N-acetylgalactosamine 4-sulfatase

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis VI

    phase 3 small molecule completed

    3 trials

  11. N01269

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  12. N1T-MC-MALO

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  13. NA_00090926

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  14. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  15. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  16. NBI-1065845-MDD3024

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  17. NBI-1065845-MDD3025

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  18. NBI-1065845-MDD3026

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  19. NBI-1065845-MDD3027

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  20. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  21. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  22. NBI-1117568-SCZ3030

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  23. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  24. NBI-74788-CAH2006

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  25. NBI-74788-CAH3003

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  26. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  27. NBI-98854-ATS3019

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  28. NCT02735707

    Disc Medicine

    Respiratory tract infection

    phase 3 small molecule active

    1 trial

  29. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)

    phase 3 small molecule terminated

    1 trial

  30. NDV-01 (sustained-release gemcitabine-docetaxel)

    RELMADA THERAPEUTICS, INC.

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    2 trials

  31. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  32. NEPA-22-01

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  33. NER1006-01/2025

    Norgine Pty.

    Colonic disease

    phase 3 small molecule active

    1 trial

  34. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  35. NGAM-12

    Maze Therapeutics

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

  36. NGAM-13

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  37. NGAM-16

    Maze Therapeutics

    Prevention of a Major infection in patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions receiving treatment with B-cell depletion therapy.

    phase 3 small molecule active

    1 trial

  38. NGF-PCED-301

    Dompe' Farmaceutici S.p.A.

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  39. NHL-014

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  40. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  41. NICOTINAMIDE, cellulose microcristalline

    ISTA Pharma Limited

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  42. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  43. NIS793

    Novartis Pharmaceuticals

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule completed

    1 trial

  44. NIVOLUMAB for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  45. NKTR-102

    Nektar Therapeutics UK Limited

    Metastasis

    phase 3 small molecule completed

    1 trial

  46. NKTR-102

    Nektar Therapeutics UK Limited

    Locally Recurrent Breast Cancer

    phase 3 small molecule completed

    1 trial

  47. NKTR-118

    AstraZeneca

    Opioid-Induced Constipation

    phase 3 small molecule terminated

    1 trial

  48. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.